Q1 2026 Presentation (04/28/2026 00: 00

Published: 2026-04-29 14:12:12 ET CDNA

Published on 04/29/2026 at 02:12 pm EDT

Q1 2026

Financial Results

April 28, 2026

John Hanna

President C Chief Executive Officer

Repeat Testing

Patient engagement pulls through

testing adherence

Solutions-Selling

Integrated testing, digital solutions

and pharmacy

High Disease Burden

Managed by a concentrated group

of specialty providers

Extend Our Leadership in Precision Medicine Diagnostics

We address markets where our core competencies

give us the right to win

#1 in Market

Clear leadership position

Innovating to Expand Leadership Position and Enter New Markets C Grow TAM

Key Pipeline Initiatives

AlloHeme

AlloSure Liver

HistoMap Kidney

AlloHeme Blood-Based Relapse Monitoring for AML and MDS

First Transplant+ Indication Expansion

AlloSure Liver Blood-Based dd-cfDNA Test for Disease Monitoring

New Solid Organ Transplant Indication

HistoMap Kidney Tissue-Based Molecular Test for Rejection Subtyping

Complementary to blood-based AlloSure

Solutions Sales

Medical Education

CareDx Cares

Software Solutions: Simplifying Workflow for Transplant Centers

EPIC AURA: Native EMR Ordering C Reporting

EPIC Enterprise: LIMS Infrastructure for Rapid Product Launches

Heart: Inform Prognosis with SHORE

Kidney: Expanded Context of Use Beyond Surveillance

Lung: Educate about ALAMO to Drive Adoption

Two Key Go-To-Market Motions

1

Clinical

Differentiation

2

Workflow Improvement

Resources Accelerating Growth in 2026

Building Belief in Molecular Testing C Simplifying Workflow for Health Systems

Building Clinical Evidence to Strengthen Adoption and Extend Market Leadership

Invest in Studies that Advance

the Utility of Our Products

Clinically Validate

Change Behavior

Improve Outcome

Inform Therapy

Solid Organ Transplant

MERIT

Therapeutic Intervention

Heart

HARBOR

Therapeutic Monitoring

Kidney

ALAMO Lung Demonstrating longitudinal utility

MAPLE

Clinical Validation

Liver

Cell Therapy s Heme Onc

ACROBAT

AML s MDS

AlloHeme

Clinical Validation

ACROSS

DLBCL s MM

CAR-T Persistence Clinical Validation

VANTx AI Clinical Research Platform

FEATURED HEART ABSTRACT

Gene Expression Profiling (GEP) and Donor-Derived Cell-Free DNA (dd-cfDNA) Levels Are Elevated Prior to Acute Rejection

Elevations in HeartCare (AlloMap Heart and AlloSure Heart) were observed months prior to acute cellular and antibody-mediated rejection.

CareDx featured in:

Abstracts total

Oral presentations

Centers' data

Including new

SHORE and ALAMO data

FEATURED LUNG ABSTRACT

Donor Derived cfDNA% Reference Change from Individualized Baseline (CIB) is Associated with Clinically Significant Loss of Spirometric-Function and Acute Lung Allograft Dysfunction Events After Lung Transplantation

Magnitude of change from personalized AlloSure Lung baseline was associated with increased risk of clinically significant lung function loss, with age-dependent differences noted in the analysis.

Largest coordinated bodies of real-world, longitudinal molecular monitoring data presented at a national transplant meeting

Sharpening Focus on Core Precision Medicine Testing Services and Patient C Digital Solutions

Simplify CareDx's

Operating Model

Sharpen Strategic Focus

Improve

Financial Flexibility

Position for Continued Success

Divested Global IVD Business with Manufacturing, Regulatory and Commercial Operations Distinct from Testing Services

Solution-Selling Strategy

is Driving Growth.

Testing Services and Patient C Digital

Solutions Delivered 48%

and 33% Revenue Growth in Q1 2026, Respectively

Upfront Cash

Consideration of $170M at Closing

Supports Capital

Allocation Strategy

Eurobio Scientific is a Long-Standing Partner with Global IVD Scale and Capabilities

Leading MRD Platform for Viral-Mediated Cancers

130,000+

Commercial Tests Performed

~2,000

Active Ordering Physicians

$1,800

ADLT Medicare Reimbursement

$34M

Estimated 2025 Revenue

56

Peer Review Publications

100

U.S. Employees

100 Million

Covered Lives

30-40%

Annual Revenue Growth

Naveris documen tation and records as of April 2026.

4 Months

Median lead time to recurrence

Recurrence-free survival

Tumor-Naïve Cancer Detection with Higher Sensitivity, Specificity and Lead Time to Recurrence

>G5%

PPV/NPV for HPV+

HCN cancer detection

56

Publications

Growing body of peer-

reviewed evidence

5 Patents

Covering Proprietary Methods to Detect Viral Cancers

Hanna GJ etal. Clin Cancer Res. 2023;29(20):4306-4313. Naveris assay documentation and issued patent portfolio (as of April 2026). TTMV® DNA: Tumor Tissue-Modified Viral DNA

Managed by Specialty Providers with Long-Term Surveillance

~80%

~20%

~60%

~40%

ANNUAL HPV CANCER INCIDENCE

~low 1000s

Gynecological

~75%

~25%

~25k

Head C Neck

HPV Drives a Large Share of Multiple Solid Tumors

Penile

~15k

Anal

~G0%

~10%

~11k

% of Cases

HPV-Attributable

Non-HPV-Attributable

HPV Cancer Incidence is Growing Shown: Head s Neck Cancer1 Rate of New Cases

13

Rate per 100,000 Persons

11

9

7

2000

2005

2010

2015

2020

Tens of thousands of new U.S. cases annually across viral-mediated cancers, with large survivor cohorts in multi-year surveillance

Source: Centers for Disease Control; SEER Database (rounded for presentation); World Health Organization; Duke Global Health Institute; National Institute of Health; Patel PR, et al. Sources of HPV Vaccine Hesitancy in Parents. Hum Vaccin Immunother. 2013 Dec;9(12):2649-53; Kong WY, et al. Disparities in Healthcare Providers' . Recommendation of HPV Vaccination for US Adolescents: A Systematic Review. Cancer Epidemiol Biomarkers. 2021 Nov;30(11):1981-1992. 1 Head and neck reflects oral cavity and pharynx cancer;

Viral-Mediated Cancer Testing Utilized from Initial Diagnosis through MRD Surveillance

Viral-Mediated Cancer

Aid to Diagnosis MRD Surveillance

Head s Neck

Clinically Validated Medicare Covered

Anal

Evidence Development Medicare Covered

Gynecologic

Planned

Jeff Teuteberg, MD

Chief Medical Officer

Aid-to-Diagnosis

MRD Surveillance

Critical Decisions

Identify Treatment

Course

ENT Evaluation Surgery, Radiation,

Chemotherapy

Therapeutic Monitoring

Treatment response C Treatment options

Relapse Monitoring

Serial monitoring for recurrence

Managed by ENT surgeons, medical and radiation oncologists at accredited centers

Based on NCCN and CAP clinical practice guidelines and peer-reviewed literature describing HPV-driven cancer diagnosis, treatment, and post-treatment molecular surveillance.

Longitudinal Care Journey Supported by Molecular Monitoring

Testing Frequency Aligned to Established Guideline Recommendations for Physician Follow-Up

Medicare Covered Naveris Testing as Represented with Head & Neck Cancer Surveillance

Years 1-2 Years 3-4 Years 6+

Year 0 Definitive Treatment

Year 1 Year 2

Year 3

Year 4

Year 5

Years 6+

Medicare coverage policies allow 14 tests per patient in the first 5 years of surveillance

John Hanna

President C Chief Executive Officer

Viral-Mediated Cancers

Established MRD Reimbursement with Expanding Aid-To-Diagnosis Indications

~$3B

Aid to Diagnosis TAM

~$1.5B

MRD TAM

Estimates based on CareDx management analyses of data on file.

Development

Validation

Launched

Indication

Multi-Indication Strategy to Accelerate Growth

Solid Organ Transplant

Heart

Kidney

Lung

Liver

Specialty Oncology

HsN Cancer

Anal Cancer

Gyn Cancer

AML/MDS

CAR-T

$12.5B

Portfolio TAM

Large, multi-year testing opportunities anchored in longitudinal care and concentrated specialty settings

$1B

Cell Therapy C Hematology

$4.5B

Viral Mediated Cancers

$1B

Digital C Patient Solutions

$6B

Solid Organ Transplant

Estimates based on CareDx management analyses of data on file.

Disclaimer

CareDx Inc. published this content on April 28, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 29, 2026 at 18:11 UTC.